Medical emergency?Emergency? Call 911. Nearest emergency roomsNearest ERs

Prescription medicine

Iberdomide

Official FDA data, not advice

Everything here comes from the U.S. Food and Drug Administration (FDA): the drug label, the NDC Directory, Drugs@FDA, recall reports and the drug shortage list. Each fact shows its source and date.

This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.

In an emergency, call 911. If someone may have taken too much of a medicine, call Poison Help: 1‑800‑222‑1222.

Quick answers

What is Iberdomide used for?
The FDA-approved label (Zenbexus, E.R. Squibb & Sons, L.L.C., August 13, 2026) says: “ZENBEXUS is indicated, in combination with daratumumab and hyaluronidase-fihj and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least 1 prior line of therapy including a proteasome inhibitor and an immunomodulatory agent. This indication is approved under accelerated approval based on minimal residual disease (MRD)-negative complete response (CR) at any time […]. …” This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
Does Iberdomide have a boxed warning?
Yes. The FDA label for Zenbexus has a boxed warning, the FDA’s strongest warning. Read it on the full label and ask your pharmacist.
Is there a shortage of Iberdomide?
No current shortage is listed by the FDA for the products of this medicine (FDA data from October 30, 2026).
Has Iberdomide been recalled?
No recall linked to the products of this medicine appears in the FDA enforcement reports we use.
Who makes Iberdomide?
1 company lists prescription products of Iberdomide in the FDA NDC Directory, including E.R. Squibb & Sons, L.L.C..

What Iberdomide is used for

Quoted from the “Indications and Usage” section of the FDA-approved label.

ZENBEXUS is indicated, in combination with daratumumab and hyaluronidase-fihj and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least 1 prior line of therapy including a proteasome inhibitor and an immunomodulatory agent. This indication is approved under accelerated approval based on minimal residual disease (MRD)-negative complete response (CR) at any time […]. …

— FDA label: Zenbexus, E.R. Squibb & Sons, L.L.C., effective August 13, 2026. Read the full label on DailyMed →

This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.

Conditions named on the label

These condition names appear word for word in the label’s “Indications and Usage” text (matched with a reviewed table). Each page lists hospitals whose own websites name the condition.

Related medical specialties

Boxed warning

A boxed warning (“black box”) is the FDA’s strongest warning on a drug label, for serious or life-threatening risks.

This label has a boxed warning. Read it on the full label →

Forms and how it is given

Dosage formsCapsule
RouteOral
Prescription products2 in the FDA NDC Directory
Brand namesZenbexus

Companies that list this medicine

Labelers in the FDA NDC Directory: the company named on the package (maker or distributor), with the number of prescription products.

FDA approval history

  • NDA: New Drug Application: how a new (usually brand-name) medicine is approved.
Brand and biologic applications
ApplicationSponsorApprovedLater changes approved
NDA221075
ZENBEXUS
Bristol Myers SquibbAugust 13, 2026 —

Shortage status

The FDA drug shortage list does not show these products.

FDA Drug Shortages database →

Recalls

No recall linked to these products (by their NDC code) appears in the FDA enforcement reports.

Official identifiers

RxCUI (RxNorm)2749737, 2749743, 2749745, 2749747
SPL set ID of the quoted label3663d9cb-3f66-48ae-bf0a-6958bc0888de
FDA labels (SPL)1
FDA applicationsNDA221075
Active ingredients (FDA)IBERDOMIDE

Sources

  1. FDA-approved label on DailyMed (National Library of Medicine) — Zenbexus, E.R. Squibb & Sons, L.L.C., effective August 13, 2026; via openFDA, FDA data exported October 30, 2026, retrieved October 31, 2026
  2. NDC Directory (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
  3. Drugs@FDA (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
  4. Drug recall enforcement reports (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 27, 2026, retrieved October 31, 2026
  5. Drug shortages (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026

openFDA data is provided by the FDA as is; it may be incomplete. Always rely on the label that comes with your medicine. FDA Enforcement Report search →

Report an error → · Information for medicine makers